REPORT FROM THE ENS 2008 – The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial demonstrated that atorvastatin 80 mg/day was effective in secondary prevention of ischemic stroke or TIA. At 4.9-year median follow-up, the absolute risk reduction for ischemic stroke with atorvastatin versus placebo was 2.2% (adjusted HR 0.78), although more hemorrhagic strokes occurred in the active treatment group (55 vs. 33; adjusted HR 1.66) (Amarenco et al. N Engl J Med 2006;355:549-59).